Cerebellar Amyloid-β Plaques: How Frequent Are They, and Do They Influence 18F-Florbetaben SUV Ratios?
暂无分享,去创建一个
Osama Sabri | Ana M Catafau | Bernardino Ghetti | James W Ironside | Santiago Bullich | Walter J Schulz-Schaeffer | Anja Hoffmann | Henryk Barthel | John P Seibyl | J. Seibyl | B. Ghetti | W. Schulz-Schaeffer | O. Sabri | H. Barthel | J. Ironside | J. Leverenz | A. Catafau | S. Bullich | Anja Hoffmann | James Leverenz
[1] A. Larner. The cerebellum in Alzheimer's disease. , 1997, Dementia and geriatric cognitive disorders.
[2] Nick C Fox,et al. Carbon-11-Pittsburgh compound B positron emission tomography imaging of amyloid deposition in presenilin 1 mutation carriers. , 2011, Brain : a journal of neurology.
[3] H. Braak,et al. Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.
[4] L. Wolfson,et al. Cardiovascular risk factors and small vessel disease of the brain: Blood pressure, white matter lesions, and functional decline in older persons , 2016, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[5] Kenneth S. Kosik,et al. The E280A presenilin 1 Alzheimer mutation produces increased Aβ42 deposition and severe cerebellar pathology , 1996, Nature Medicine.
[6] John Seibyl,et al. Impact of Training Method on the Robustness of the Visual Assessment of 18F-Florbetaben PET Scans: Results from a Phase-3 Study , 2016, The Journal of Nuclear Medicine.
[7] H. Braak,et al. Phases of Aβ-deposition in the human brain and its relevance for the development of AD , 2002, Neurology.
[8] D. Selkoe,et al. Diffuse senile plaques occur commonly in the cerebellum in Alzheimer's disease. , 1989, The American journal of pathology.
[9] William D Rooney,et al. Longitudinal relaxographic imaging of white matter hyperintensities in the elderly , 2014, Fluids and Barriers of the CNS.
[10] S. DeKosky,et al. Kinetic Modeling of Amyloid Binding in Humans using PET Imaging and Pittsburgh Compound-B , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[11] L. Dinkelborg,et al. Piramal Imaging. , 2015, Neurodegenerative disease management.
[12] Lennart Thurfjell,et al. The influence of biological and technical factors on quantitative analysis of amyloid PET: Points to consider and recommendations for controlling variability in longitudinal data , 2015, Alzheimer's & Dementia.
[13] S. Hirai,et al. Diffuse type of senile plaques in the cerebellum of Alzheimer-type dementia demonstrated byβ protein immunostain , 2004, Acta Neuropathologica.
[14] W. Markesbery,et al. Progression of regional neuropathology in Alzheimer disease and normal elderly: findings from the Nun study. , 1999, Alzheimer disease and associated disorders.
[15] B. Jasani,et al. The distribution of amyloid plaques in the cerebellum and brain stem in Down's syndrome and Alzheimer's disease: a light microscopical analysis , 2004, Acta Neuropathologica.
[16] H. Braak,et al. Alzheimer's disease: Mismatch between amyloid plaques and neuritic plaques , 1989, Neuroscience Letters.
[17] B. Ghetti,et al. Spectrum of amyloid β-protein immunoreactivity in hereditary Alzheimer disease with a guanine to thymine missence change at position 1924 of the APP gene , 1992, Brain Research.
[18] C. Rowe,et al. Amyloid imaging in therapeutic trials: The quest for the optimal reference region , 2015, Alzheimer's & Dementia.
[19] Majaz Moonis,et al. Amyloid Deposition Begins in the Striatum of Presenilin-1 Mutation Carriers from Two Unrelated Pedigrees , 2007, The Journal of Neuroscience.
[20] S. M. Sumi,et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.
[21] Lutz Tellmann,et al. Comparison of cerebral blood flow acquired by simultaneous [15O]water positron emission tomography and arterial spin labeling magnetic resonance imaging , 2014, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[22] John Seibyl,et al. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study , 2015, Alzheimer's & Dementia.
[23] Cerebral amyloid angiopathy and intracerebral hemorrhage with special reference to the pons. , 1994, Clinical neuropathology.
[24] P. Wood. The Cerebellum in AD , 2003 .
[25] C. Rowe,et al. 18F-Florbetaben (FBB) PET SUVR quantification: Which reference region? , 2015 .
[26] John Seibyl,et al. Aβ imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study , 2014, Journal of Neurology, Neurosurgery & Psychiatry.
[27] Lennart Thurfjell,et al. Automated Quantification of 18F-Flutemetamol PET Activity for Categorizing Scans as Negative or Positive for Brain Amyloid: Concordance with Visual Image Reads , 2014, The Journal of Nuclear Medicine.
[28] R. Waggoner,et al. FAMILIAL ORGANIC PSYCHOSIS (ALZHEIMER'S TYPE) , 1934 .
[29] N. Foster,et al. Preserved Pontine Glucose Metabolism in Alzheimer Disease: A Reference Region for Functional Brain Image (PET) Analysis , 1995, Journal of computer assisted tomography.
[30] John Seibyl,et al. Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study , 2011, The Lancet Neurology.
[31] Matthew L Senjem,et al. Functional impact of white matter hyperintensities in cognitively normal elderly subjects. , 2010, Archives of neurology.